Following immune changes in people with chronic hepatitis B over time
Follows people with chronic hepatitis B, aged 1 to 80, to study immune changes.
Plain-language title generated from the registry record
Registry title: Immune Dynamics in the Natural History of Chronic HBV Infection
Key facts
- Where
- Guangzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 80 years old?
Source: NCT07137247, who can take part
Where in China
- Nanfang Hospital, Southern Medical UniversityGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nanfang Hospital, Southern Medical University
- Trial code
- NCT07137247
- Record updated
- 30 September 2025
- Original description
The purpose of this observational study is to follow up on chronic HBV-infected patients over a long period of time to understand the changes in the immune status as age increases and the natural history of chronic HBV infection progresses. The main questions it aims to answer are:Read full original descriptionShow less
Immune Dynamics in the Natural History of Chronic HBV Infection
The purpose of this observational study is to follow up on chronic HBV-infected patients over a long period of time to understand the changes in the immune status as age increases and the natural history of chronic HBV infection progresses. The main questions it aims to answer are:
* Does the natural history of chronic HBV infection progress with changes in HBV-specific immunity? * What is the role of age in the natural history of chronic HBV infection?
Patients with chronic HBV infection who are untreated and aged 1-80 years will be followed up every six months. During each follow-up, HBV-related serological and virological indicators will be tested. Peripheral blood samples will also be collected to test HBV-specific immunity and the immune environment.
Inclusion: Aged 1-80 years, either male or female; Patients diagnosed with chronic hepatitis B virus infection in accordance with the "Guidelines for the Prevention and Treatment of Chronic Hepatitis B" (2019 edition); No antiviral treatment (including nucleoside analogs and interferons, etc.) within the past six months.
Exclusion: Concurrent Infections and Liver Diseases: Exclusion of patients with concurrent HCV or HIV infection, alcoholic fatty liver disease, non-alcoholic fatty liver disease, autoimmune liver diseases; Immune and Coagulation System Disorders: Exclusion of patients with immune system diseases such as hyperthyroidism, coagulation system disorders such as diabetes mellitus or idiopathic thrombocytopenic purpura; Severe Underlying Diseases. Exclusion of patients with severe underlying diseases that affect the body's immune status; Other Unsuitable Conditions:; Exclusion of patients whom the investigator deems to have other conditions that make them unsuitable for enrollment.